Drug Science Policy and Law
September 1, 2025
David Nutt, David Erritzøe, Anne Katrin Schlag et al.
9 citations
Psychedelics are undergoing a clinical research renaissance, with compounds such as psilocybin advancing to Phase 3 trials for treatment-resistant depression and receiving fast-track or breakthrough designations from regulatory agencies. Despite this progress, the field lacks standardized terminology to guide clinical development, dosing, safety monitoring, and regulatory classification. Here,...
Research Square
September 23, 2022
M. Grifell, Guillem Mir, Roger Estelrich-Azubide et al.
Abstract Background Despite the proliferation of new psychoactive substances (NPS) in recent years, there are many gaps in our understanding of the phenomena. Current methodologies still fail to provide timely and scientifically reliable knowledge between controlled trials and online data reports that lack analytical confirmation of the reported substances. This study tests a new online,...
Biology
March 24, 2021
Nunzia La Maida, Esther Papaseit, Lucía Martínez de Soto et al.
14 citations
Synthetic cannabinoids (SCs) are one of the most frequent classes of new psychoactive substances monitored by the EU Early Warning System and World Health Organization. UR-144 is a SC with a relative low affinity for the CB1 receptor with respect to that for the CB2 receptor. As with other cannabinoid receptor agonists, it has been monitored by the EU Early Warning System since 2012 for severe...
Journal of Psychoactive Drugs
June 1, 2017
Álvaro José Palma-Conesa, Mireia Ventura, Liliana Galindo et al.
65 citations
New psychoactive tryptamines may be a public health risk since they intend to mimic the hallucinogenic effects of regulated psychoactive drugs. Few studies describe uses and clinical effects of unregulated new psychoactive tryptamines. This study aims (1) to explore the presence of tryptamines classified as NPS among the substances delivered for analysis to a harm-reduction organization; (2) to...
European Psychiatry
April 1, 2017
Amira Trabsa, E. Monteagudo, D.d. Mariona et al.
2 citations
Introduction Although psychoactive substances has a long history in recreational settings, research on its composition has focused only on tablets, crystal and powder, even though new formulation for new psychoactive substances are readily available for users. Objectives To describe the presence of psychoactive substances and its characteristics in new formulations which had not previously been...
European Psychiatry
March 1, 2016
I. Ezquiaga, M. Grifell, Liliana Galindo et al.
IntroductionNovel psychoactive substances (NPS) use is progressively increasing year on year. A new group of phenethylamines sold as legal stimulants and hallucinogens is being reported increasingly since 2012. Within this group, 25I-NBOMe is an outstanding substance with powerful effects and high affinity with the serotonin 2a (5HT2a) receptor. Several toxicity cases have been reported so...